Heron Therapeutics (NASDAQ:HRTX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Heron Therapeutics (NASDAQ:HRTX) released its earnings results on Monday. The biotechnology company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01), FiscalAI reports. The firm had revenue of $34.71 million during the quarter, compared to the consensus estimate of $36.72 million.

Here are the key takeaways from Heron Therapeutics’ conference call:

• Net product sales were $34.7 million in Q1, modestly below plan after seasonal co-pay resets and two weeks of severe weather that sharply reduced elective surgeries; management notes March recovered to >$15M and expects rescheduled procedures to provide a tailwind through 2026.
• Acute care momentum — acute revenue grew 32% YoY with ZYNRELEF up 27% and APONVIE >50%; ZYNRELEF demand units rose 22% YoY and Ignite 2.0 expanded targeted accounts by 38%, supporting a planned Q3 salesforce expansion.
• APONVIE commercial and clinical catalysts — demand units grew 68% YoY, ordering accounts hit an all?time high, a permanent J?Code became active April 1, and APONVIE received an A1 evidence rating and prominent inclusion in the 5th consensus PONV guidelines.
• CINVANTI stability — maintained a ~25% NK1 market share and consistent ordering patterns despite competition, with the REIGNITE program and aprepitant salesforce expansion expected to add roughly $10M of annualized revenue from new accounts.
• Margin and temporary supply cost pressure — growth margin dipped to 69% and adjusted EBITDA was negative $0.7M due in part to higher-cost batches from a secondary CINVANTI supplier; the company expects this to work through over the next two quarters and has reaffirmed full?year guidance of $173–183M sales and $10–20M adjusted EBITDA.

Heron Therapeutics Stock Performance

NASDAQ HRTX traded down $0.28 during trading hours on Monday, hitting $0.93. The company had a trading volume of 5,246,648 shares, compared to its average volume of 1,928,451. Heron Therapeutics has a fifty-two week low of $0.74 and a fifty-two week high of $2.30. The company has a quick ratio of 1.51, a current ratio of 2.48 and a debt-to-equity ratio of 10.59. The business has a fifty day simple moving average of $0.97 and a 200-day simple moving average of $1.16. The firm has a market cap of $175.62 million, a P/E ratio of -7.16 and a beta of 1.70.

Institutional Investors Weigh In On Heron Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC increased its holdings in shares of Heron Therapeutics by 2,383.4% during the fourth quarter. Advisory Services Network LLC now owns 18,874 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 18,114 shares during the period. B. Riley Wealth Advisors Inc. acquired a new position in shares of Heron Therapeutics during the second quarter valued at $26,000. Voleon Capital Management LP acquired a new position in shares of Heron Therapeutics during the third quarter valued at $34,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Heron Therapeutics during the third quarter valued at $34,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Heron Therapeutics during the second quarter valued at $43,000. 80.01% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on HRTX shares. Zacks Research cut Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, April 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Heron Therapeutics has a consensus rating of “Hold” and an average price target of $4.50.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.